NewBiologix, a technology innovation company enabling efficient, cost-effective, and scalable production of viral vectors for cell and gene therapy (C>), today announced it has granted a non-exclusive technology license to Recipharm Advanced Bio – Recipharm’s Advanced Therapies (ATMP) division and a leading Contract Development and Manufacturing Organization (CDMO) – to provide global biotech and pharma companies with access to NewBiologix’s Xcell-Eng-HEK293 cell lines.
The Xcell-Eng-HEK293 cell lines are high-value solutions for manufacturing recombinant adeno-associated viruses (rAAV) for use in C>. NewBiologix provides cGMP-ready, high-yield, viral particle-producing cell lines and manufacturing technologies for developing gene therapies. This unique cell line enables customers to speed up development and quickly advance C> programs to clinical trials. NewBiologix uses advanced technologies combining multidimensional digital PCR with third-generation sequencing. Its tightly controlled cell line coupled with Recipharm Advanced Bio’s AAV manufacturing platform leads to excellent scalability and consistent high yields at multiple scales across a wide range of serotypes.
As a result of proprietary innovations and sustained process development efforts using NewBiologix’s cell lines, Recipharm Advanced Bio has achieved industry-leading results across multiple AAV programs. It consistently exceeds 2E15 vg/L, even with large (~5kb) gene-of-interest constructs, demonstrating remarkable process robustness and reproducibility. By combining its proprietary packaging plasmid system with NewBiologix’s advanced HEK293 cell line and downstream purification toolbox, Recipharm Advanced Bio delivers >95% full capsids in final product formulations.
In addition, Recipharm Advanced Bio has validated high-yield, high-purity AAV production across more than 10 rAAV serotypes, supporting broad therapeutic applicability. Its fully integrated offering, from research-use only (RUO) through to GMP manufacturing, provides a seamless, scalable path to clinic and market for advanced therapy developers.
